Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | NMT2 | O60551 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31385440 | 1.00 | GHSR (0.41) | GHSRMEN1KMT2ACPB2KDM1A | |
| SCHEMBL29588633 | 1.00 | GHSR (0.41) | GHSRMEN1KMT2ACPB2KDM1A | |
| SCHEMBL9120793 | 1.00 | GHSR (0.41) | GHSRMEN1KMT2ACPB2KDM1A | |
| SCHEMBL30008261 | 0.96 | NMT1 (0.44) | GHSRMEN1KMT2ACPB2KDM1A | |
| SCHEMBL29679965 | 0.95 | KDM1A (0.43) | GHSRMEN1KMT2ACPB2KDM1A | |
| SCHEMBL29496543 | 0.95 | MEN1 (0.44) | GHSRMEN1KMT2AKDM1APRCP | |
| SCHEMBL29824782 | 0.92 | NMT1 (0.40) | MEN1KMT2ACPB2NMT2NMT1 | |
| SCHEMBL30938813 | 0.92 | GHSR (0.40) | GHSRKDM1ANMT2NMT1PRCP | |
| SCHEMBL5402328 | 0.91 | KDM1A (0.44) | GHSRCPB2KDM1AREN | |
| SCHEMBL30844292 | 0.91 | KDM1A (0.44) | GHSRCPB2KDM1AREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472223-B2 | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD154 interaction | OP-T LLC (US) | 2025-11-18 | — | — | US | claimed |
| US-12472223-B2 | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD154 interaction | OP-T LLC (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250101063-A1 | POLYPEPTIDE COMPOUND AND USE THEREOF IN TREATMENT OF ENTERITIS | SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) | 2025-03-27 | — | — | US | disclosed |
| EP-4467562-A1 | POLYPEPTIDE COMPOUND AND USE THEREOF IN TREATMENT OF ENTERITIS | Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd (CN) | 2024-11-27 | — | — | EP | disclosed |
| US-11793854-B2 | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction | OP-T LLC (US) | 2023-10-24 | — | — | US | disclosed |